DK3441474T3 - Farmaceutiske sammensætninger indeholdende et muteret leukocidin e - Google Patents
Farmaceutiske sammensætninger indeholdende et muteret leukocidin e Download PDFInfo
- Publication number
- DK3441474T3 DK3441474T3 DK18193473.8T DK18193473T DK3441474T3 DK 3441474 T3 DK3441474 T3 DK 3441474T3 DK 18193473 T DK18193473 T DK 18193473T DK 3441474 T3 DK3441474 T3 DK 3441474T3
- Authority
- DK
- Denmark
- Prior art keywords
- leucocidine
- muttered
- pharmaceutical compositions
- compositions containing
- pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361836516P | 2013-06-18 | 2013-06-18 | |
EP14813300.2A EP3011012B1 (en) | 2013-06-18 | 2014-06-18 | Cellular factors involved in the cytotoxicity of staphylococcus aureus leukocidins: novel therapeutic targets |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3441474T3 true DK3441474T3 (da) | 2020-08-17 |
Family
ID=52105502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18193473.8T DK3441474T3 (da) | 2013-06-18 | 2014-06-18 | Farmaceutiske sammensætninger indeholdende et muteret leukocidin e |
Country Status (8)
Country | Link |
---|---|
US (4) | US10301378B2 (da) |
EP (3) | EP3441474B1 (da) |
JP (3) | JP2016528185A (da) |
CN (2) | CN105722972A (da) |
DK (1) | DK3441474T3 (da) |
ES (1) | ES2811527T3 (da) |
HK (1) | HK1223978A1 (da) |
WO (1) | WO2014205127A2 (da) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105722972A (zh) * | 2013-06-18 | 2016-06-29 | 纽约大学 | 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素:新型治疗靶点 |
EP3409277A1 (en) * | 2017-05-30 | 2018-12-05 | Dompé farmaceutici s.p.a. | Il-8 inhibitors for use in the treatment and/or prevention of bacterial secondary infections |
WO2019113096A1 (en) | 2017-12-05 | 2019-06-13 | BioPlx, Inc. | Methods and compositions to prevent microbial infection |
CN107802822B (zh) * | 2017-12-11 | 2021-09-17 | 马筱玲 | 金黄色葡萄球菌毒素LukS-PV在制备治疗实体肿瘤药物中的应用 |
KR102061735B1 (ko) * | 2018-06-08 | 2020-01-02 | 대한민국(농림축산식품부 농림축산검역본부장) | 황색포도알균 약독화 장독소 및 세포독소 재조합 단백질을 포함하는 백신 조성물 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
EP0892808B1 (en) | 1996-04-12 | 2008-05-14 | PHRI Properties, Inc. | Detection probes, kits and assays |
US6037130A (en) | 1998-07-28 | 2000-03-14 | The Public Health Institute Of The City Of New York, Inc. | Wavelength-shifting probes and primers and their use in assays and kits |
SE9903544D0 (sv) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
CA2439452C (en) | 2001-03-01 | 2012-05-15 | University Of Saskatchewan Technologies Inc. | High-affinity antagonists of elr-cxc chemokines |
GB0107661D0 (en) * | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
GB0221829D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
CN1984899B (zh) | 2004-05-12 | 2011-07-27 | 先灵公司 | Cxcr1和cxcr2趋化因子拮抗剂 |
EP2021475B1 (en) * | 2006-05-16 | 2011-10-26 | University of Saskatchewan | High-affinity antagonists of elr-cxc chemokines |
PL2024329T3 (pl) | 2006-05-18 | 2014-03-31 | Dompe Farm Spa | (2r)-2-[(4-sulfonylo)aminofenylo]propanoamidy i zawierające je kompozycje farmaceutyczne |
TW200744632A (en) * | 2006-06-12 | 2007-12-16 | Nabi Biopharmaceuticals | Use of alpha-toxin for treating and preventing staphylococcus infections |
BRPI0713647A2 (pt) | 2006-06-12 | 2012-10-23 | Schering Corp | formulações farmacêuticas e composições de um antagonista seletivo cxcr2 ou cxcr1 e métodos para o uso do mesmo visando o tratamento de distúrbios inflamatórios |
EP2094697A1 (en) | 2006-11-23 | 2009-09-02 | Novartis AG | 5-sulfanylmethyl-pyrazolo [1,5-a]pyrimidin-7-ol derivatives as cxcr2 antagonists |
KR20160029870A (ko) * | 2008-04-21 | 2016-03-15 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
UA103198C2 (en) | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
EP3725775A1 (en) | 2009-02-17 | 2020-10-21 | Syntrix Biosystems, Inc. | Pyridine- and pyrimidinecarboxamides as cxcr2 modulators |
EP2419129A2 (en) * | 2009-04-14 | 2012-02-22 | Novartis AG | Compositions for immunising against staphylococcus aerus |
EP2308484A1 (en) | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets |
ES2605476T3 (es) | 2010-05-05 | 2017-03-14 | New York University | Leucocidinas de Staphylococcus aureus, composiciones terapéuticas, y sus usos |
JP6486002B2 (ja) | 2010-08-23 | 2019-03-20 | シントリックス・バイオシステムズ・インコーポレイテッドSyntrix Biosystems, Inc. | Cxcr2モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド |
JP6093760B2 (ja) | 2011-06-19 | 2017-03-08 | ニューヨーク・ユニバーシティ | 抗炎症剤および殺菌剤としてのロイコトキシンe/d |
BR112013032774B1 (pt) | 2011-06-19 | 2020-05-05 | Univ New York | composições compreendendo proteína luke isolada ou polipeptídeo da mesma, uma proteína lukd isolada ou polipeptídeo da mesma ou sua combinação, bem como seu uso |
US9046530B2 (en) * | 2011-12-02 | 2015-06-02 | Board Of Regents, The University Of Texas System | Methods and compositions for chlamydial antigens as reagents for diagnosis of tubal factor infertility and chlamydial infection |
SI2785368T1 (sl) * | 2011-12-02 | 2019-08-30 | Integrated Biotherapeutics, Inc. | Imunogen sestavek, ki vsebuje polipeptide pridobljene iz panton-valentin levkocidina (PVL) |
US9914767B2 (en) * | 2012-04-17 | 2018-03-13 | Arsanis Biosciences Gmbh | Cross-reactive Staphylococcus aureus antibody |
CN105722972A (zh) | 2013-06-18 | 2016-06-29 | 纽约大学 | 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素:新型治疗靶点 |
-
2014
- 2014-06-18 CN CN201480045457.2A patent/CN105722972A/zh active Pending
- 2014-06-18 EP EP18193473.8A patent/EP3441474B1/en active Active
- 2014-06-18 ES ES18193473T patent/ES2811527T3/es active Active
- 2014-06-18 US US14/899,977 patent/US10301378B2/en active Active
- 2014-06-18 DK DK18193473.8T patent/DK3441474T3/da active
- 2014-06-18 WO PCT/US2014/043021 patent/WO2014205127A2/en active Application Filing
- 2014-06-18 EP EP20187045.8A patent/EP3848046A1/en not_active Withdrawn
- 2014-06-18 JP JP2016521554A patent/JP2016528185A/ja active Pending
- 2014-06-18 EP EP14813300.2A patent/EP3011012B1/en active Active
- 2014-06-18 CN CN201910629216.7A patent/CN110420316A/zh active Pending
-
2016
- 2016-10-27 HK HK16112346.8A patent/HK1223978A1/zh unknown
-
2019
- 2019-04-24 US US16/393,249 patent/US20190248876A1/en not_active Abandoned
- 2019-07-02 JP JP2019123294A patent/JP6990674B2/ja active Active
-
2020
- 2020-06-05 US US16/894,500 patent/US11453715B2/en active Active
-
2021
- 2021-07-02 JP JP2021110607A patent/JP2021155456A/ja active Pending
-
2022
- 2022-09-14 US US17/932,109 patent/US11932683B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3441474A1 (en) | 2019-02-13 |
US20160168233A1 (en) | 2016-06-16 |
US20190248876A1 (en) | 2019-08-15 |
ES2811527T3 (es) | 2021-03-12 |
EP3441474B1 (en) | 2020-07-22 |
EP3848046A1 (en) | 2021-07-14 |
WO2014205127A3 (en) | 2015-04-02 |
JP2021155456A (ja) | 2021-10-07 |
US11932683B2 (en) | 2024-03-19 |
EP3011012B1 (en) | 2018-09-12 |
JP6990674B2 (ja) | 2022-02-03 |
EP3011012A4 (en) | 2017-01-04 |
US10301378B2 (en) | 2019-05-28 |
HK1223978A1 (zh) | 2017-08-11 |
US20230151081A1 (en) | 2023-05-18 |
CN110420316A (zh) | 2019-11-08 |
JP2019178164A (ja) | 2019-10-17 |
US11453715B2 (en) | 2022-09-27 |
US20210009664A1 (en) | 2021-01-14 |
CN105722972A (zh) | 2016-06-29 |
WO2014205127A2 (en) | 2014-12-24 |
JP2016528185A (ja) | 2016-09-15 |
EP3011012A2 (en) | 2016-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3030262T3 (da) | Kombineret farmaceutisk sammensætning | |
DK2970389T3 (da) | Farmaceutiske forbindelser | |
LT3060041T (lt) | Prostaciklino junginiai | |
HUE037275T2 (hu) | Gyógyszer-kombináció | |
DK2970336T3 (da) | Tetrahydropyrrolothiazinforbindelser | |
ME03359B (me) | 2 suptiтuisana cefemska jedinjenja | |
PT3079666T (pt) | Composições farmacêuticas que contêm fumarato de dimetilo | |
DK3043778T3 (da) | Farmaceutiske sammensætninger, der indeholder refametinib | |
HUE047544T2 (hu) | Inszekticid hatású vegyületek | |
DOS2013000177S (es) | Capsulas | |
IL244260A0 (en) | A delayed release drug formulation | |
CL2014000864S1 (es) | Envase de medicamento | |
BR302013004478S1 (pt) | Configuração aplicada a frasco | |
CL2014000866S1 (es) | Envase de medicamento | |
DK2988733T3 (da) | Farmaceutisk sammensætning indeholdende krystallin macitentan | |
IL240904A0 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
BR112016014774A2 (pt) | Compostos inseticidas | |
DK3441474T3 (da) | Farmaceutiske sammensætninger indeholdende et muteret leukocidin e | |
HK1213564A1 (zh) | 新的 -二氫- -異喹啉- -酮和 -二氫-異吲哚- -酮化合物 | |
DK2975989T3 (da) | Dispenseranordning | |
ES1078888Y (es) | Sosten modular | |
EP3060191C0 (en) | A dispenser | |
BR302014000625S1 (pt) | Configuração aplicada a garrafa | |
PL2922571T3 (pl) | Postać farmaceutyczna zawierająca metaloporfiryny zawierające karboran | |
ES1084079Y (es) | Dosificador de Pastillas |